摘要
目的:探讨晚期非小细胞肺癌(NSCLC)核苷酸切除修复交叉互补基因1(ERCC1)表达与基于顺铂化疗疗效的关系.方法:入组的81例ⅢB期及IV期NSCLC患者按1∶2随机分成对照组和基因组,基因组按肿瘤组织中ERCC1蛋白表达分成高表达组和低表达组,对照组和低表达组接受紫杉醇+顺铂化疗,高表达组接受紫杉醇+吉西他滨化疗,并对化疗疗效及生存时间进行分析.结果:完成试验的79例患者中,对照组化疗有效率(CR+PR)为30.8%(8/26),低于基因组54.7%(29/53)和ERCC1阴性组60.7%(17/28),P值分别为0.045和0.027.各组中位生存期(OS)和无进展生存期(PFS)差别无显著性,P均>0.05.结论:NSCLC患者肿瘤组织中ERCC1表达水平可作为顺铂化疗疗效的标记物,根据ERCC1表达水平选择个体化化疗方案可提高NSCLC患者化疗有效率.
AIM： To investigate the correlation between the expression of ERCC1 and therapeutic effect based on cisplatin chemotherapy in patients with advanced non-small cell lung cancer （NSCLC）. METHODS： Eighty-one stage Ⅲ B and Ⅳ NSCLC patients were enrolled in the study. The patients were randomly assigned in a 1：2 ratio to control group or ERCC1 genotypic group. ERCC1 genotypic group was further divided into ERCC1 negative group or ERCCl positive group according to the immuno-histochemical staining of samples. The patients in control group and ERCC1 negative group received paclitaxel plus cisplatin chemotherapy while the patients in ERCC1 positive group received paclitaxel plus gemcitabine chemotherapy. The data of therapeutical effect and survival time were collected and analyzed. RESULTS： Of the remaining 79 patients, the overall response rate （CR＋PR） in control group was 30.8% （ 8/26 ） , obviously lower than those in ERCC1 genotypic group （54.7% , 29/53） and in ERCC1 negative group （60.7%, 17/28） （P=0.045 and P=0.027 respectively）. However, there was no remarkable difference between the three groups in the overall survival （OS） and progression-free survival （PFS） , （P =0. 186 and P =0.245 respec-tively）. CONCLUSION： The expression of ERCC1 in NSCLC samples may be considered a therapeutic effect biomarker of chemotherapy based on cisplatin. Selection of individualized therapy based on ERCC1 expression may improve the response rate of NSCLC patients.
出处
《第四军医大学学报》
北大核心
2009年第4期351-354,共4页
Journal of the Fourth Military Medical University
